RET and lung carcinoma: As the third kinase fusion gene in lung cancer, RET fusions own therapeutic significance, because they are targetable with several US Food and Drug Administration (FDA) approved multikinase inhibitors with anti-RET activity, including Vandetanib, Cabozantinib, Lenvatinib, Alectinib, Sunitinib, Regorafenib, and Sorafenib, with response rates ranging between 16% and 47% and median progression-free survivals (PFS) ranging from 2.3 to 7.3 months7–10.